Abstract
In this work will apply mixture models based on distributions from the SMSN family to antibody data against four SARS-CoV-2 virus antigens. Furthermore, since the true infection status of individuals is known a priori, performance measures will be calculated for the methods proposed for cutoff point estimation such as sensitivity, specificity and accuracy. The results of a simulation study will also be presented.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funded by FCT - Fundacao para a Ciencia e a Tecnologia, Portugal, through the project UIDB/00006/2020
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
tmdomingues{at}fc.ul.pt
mhnunes{at}fc.ul.pt
nunosep{at}gmail.com
Data Availability
All data produced are available online at https://github.com/MWhite-InstitutPasteur/SARSCoV2SeroDXphase2
https://github.com/MWhite-InstitutPasteur/SARSCoV2SeroDXphase2